Cancer Stem Cells Accelerate Macrophage Aging

Cancer stem cells (CSCs), the key architects of tumors, drive the premature aging of macrophages in mice with robust immune systems, creating an environment conducive to tumor development. While previous studies predominantly examined CSCs in isolation or within immunodeficient mouse models, researchers from Hokkaido University's Institute for Genetic Medicine, under Haruka Wada's leadership, explored how these cells evade immune responses in a more realistic setting.

Their study, published in the Journal for ImmunoTherapy of Cancer, found that CSCs induce senescence—cellular aging—in macrophages, the initial line of defense against cancer cells. The study, conducted using glioblastoma tumor cell lines, demonstrates that cancer stem cells hindered macrophage proliferation. Importantly, macrophages cultivated with CSCs exhibited senescence, influencing not only macrophages but also suppressing T-cell antitumor activity.

The team identified interleukin 6 (IL-6), produced by CSCs, as the catalyst behind these effects. Strikingly, administering nicotinamide mononucleotide to mice injected with CSCs fostered the proliferation of non-senescent macrophages, diminishing immunosuppressive factors. This intervention not only curbed tumor growth but also extended survival times in the mice.

Wada believes that drugs targeting senescent macrophages could be a promising cancer treatment, presenting a novel approach to impeding tumor onset and recurrence after cancer treatment.